AAN 2023

Questions discussed in this category

In light of the FDA approval of tofersen for SOD1-related ALS, what is your approach to counseling people who are presymptomatic genetic carriers of one of the monogenic ALS genes?

What do you recommend for surveillance and when to start the “three R’s” (riluzole, radicava/edaravone, and relyvrio (sodium PB/TUDC...

1 Answer available

Papers discussed in this category

Neurotherapeutics, 2022 May 18

Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study.

N Engl J Med, 2022 Sep 22

Trial of Antisense Oligonucleotide Tofersen for ALS.

Related Topics